Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000869 · ClinicalTrials.gov registry record · Phase 3
A Study of Nevirapine for the Prevention of HIV Transmission From Mothers to Their Babies
A Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 2,009
- Enrollment target
NCT00000869: Completed Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00000869 is a Phase 3 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 2,009 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (160% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000869, a Phase 3 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,009 participants
- Enrollment target
Study Summary
The purpose of this study is to see if giving the anti-HIV drug nevirapine (NVP) to HIV-positive pregnant women and their babies can help reduce the chance that a mother will give HIV to her baby during delivery. This study will also test the safety of the drug and see how well it is tolerated by the mother and her baby. Previous studies suggest that NVP is a promising medication for blocking HIV transmission from HIV-positive mothers to their babies.
Interventions
- DRUG Nevirapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,009 participants |
| Est. Completion | 2001-05 |
| Phase | Phase 3 |
What the finished NCT00000869 record still lists
NCT00000869 is an interventional study that assigns participants to a tested intervention. Its 2,009 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (160% higher).
The record links to 0 conditions, and to 1 intervention - of which Nevirapine is the first listed.
NCT00000869 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00000869 about?
NCT00000869 is a clinical study titled "A Study of Nevirapine for the Prevention of HIV Transmission From Mothers to Their Babies". The purpose of this study is to see if giving the anti-HIV drug nevirapine (NVP) to HIV-positive pregnant women and their babies can help reduce the chance that a mother will give HIV to her baby during delivery. This study will also test the safety of the drug and see how well it is tolerated by th...
What is the current status of trial NCT00000869?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,009 participants. Estimated completion is 2001-05.
What interventions are being tested in trial NCT00000869?
The interventions under investigation include: Nevirapine (DRUG).
Who is sponsoring clinical trial NCT00000869?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00000869's enrollment target sits among peer trials
2,009 100th of 2000 higher than 1,901 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04100564 · 2,009 participants · NA
LITES Task Order 0005 Prehospital Airway Control Trial (PACT)
- NCT04604509 · 2,010 participants · Phase 4
Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders